BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. (Q40307963)
Jump to navigation
Jump to search
scientific article published on 7 March 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. |
scientific article published on 7 March 2006 |
Statements
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer (English)
Seiji Nagashima
Mikio Oka
Takeshi Kitazaki
Ken Shiozawa
Yoichi Nakamura
Masaaki Takemura
Hikaru Yabuuchi
Minoru Fukuda
Kazuhiro Tsukamoto